Boston Scientific (BSX) EPS (Weighted Average and Diluted) (2009 - 2026)

Boston Scientific has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $0.9 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.9, up 100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.39 (up 74.45% YoY), and the FY2025 annual result was $1.94, up 55.2% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.9 for Q1 2026 at Boston Scientific, up from $0.45 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.9 in Q1 2026 to a low of $0.07 in Q1 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.33 (2024), against an average of $0.33.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 69.57% in 2022 and soared 277.78% in 2023, its largest moves.
• Boston Scientific's EPS (Weighted Average and Diluted) stood at $0.09 in 2022, then jumped by 277.78% to $0.34 in 2023, then advanced by 11.76% to $0.38 in 2024, then increased by 18.42% to $0.45 in 2025, then surged by 100.0% to $0.9 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.9 (Q1 2026), $0.45 (Q4 2025), and $0.51 (Q3 2025), per Business Quant data.